CEBP Frontiers in Cancer Prevention Research - 2008 Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guillemette, C.
Right arrow Articles by Hunter, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guillemette, C.
Right arrow Articles by Hunter, D. J.
Cancer Epidemiology Biomarkers & Prevention Vol. 10, 711-714, June 2001
© 2001 American Association for Cancer Research

Short Communication

Association of Genetic Polymorphisms in UGT1A1 with Breast Cancer and Plasma Hormone Levels1

Chantal Guillemette2, Immaculata De Vivo, Susan E. Hankinson, Christopher A. Haiman, Donna Spiegelman, David E. Housman and David J. Hunter

Oncology and Molecular Endocrinology Research Center, Laval University Medical Center (CHUL), Faculty of Pharmacy, Laval University, Quebec G1V 4G2, Canada [C. G.]; Department of Biology and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139 [C. G., D. E. H.]; Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02115 [I. D. V., S. E. H., D. J. H.]; Departments of Epidemiology [I. D. V., S. E. H., C. A. H., D. S., D. J. H.] and Nutrition [D. J. H.], Harvard School of Public Health, Boston, Massachusetts 02115; and Harvard Center for Cancer Prevention, Boston, Massachusetts 02115 [C. A. H., D. J. H.]


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
UDP-glucuronosyltransferases (UGTs) catalyze the detoxification and the elimination of a large number of endogenous and exogenous compounds in the liver and extrahepatic tissues. One of the UGT1A family members, UGT1A1, is involved in estradiol metabolism and, therefore, represents a candidate gene in breast carcinogenesis. A common insertion/deletion polymorphism in the TATA-box of the promoter region of UGT1A1 results in decreased initiation of transcription. In a previous study, we found a positive association between the UGT1A1 low-transcriptional alleles and premenopausal breast cancer risk in an African-American population. In the present study, we sought to determine whether the low-transcription UGT1A1 promoter allele, UGT1A1*28 [A(TA)7TAA], was associated with increased breast cancer risk among primarily Caucasian women in a nested case-control study within the Nurses’ Health Study cohort. No significant association between the UGT1A1*28 [A(TA)7TAA] allele and breast cancer was observed. Compared with women homozygous for the UGT1A1*1 [A(TA)6TAA] allele, the relative risk was 0.80 (confidence interval, 0.49–1.29) for women homozygous for the UGT1A1*28 allele. The effect of the UGT1A1 genotype on plasma hormone levels in postmenopausal women not using hormone replacement was also evaluated, and overall, no significant differences in hormone levels by genotypes were observed. When restricted to women who had at least one UGT1A1*28 allele and a body mass index at blood draw of >27 kg/m2, particularly in combination with the cytochrome p450c17{alpha} genotype, estrone and estradiol levels tended to vary by UGT1A1 genotypes. The results presented do not support a strong association between the UGT1A1 promoter polymorphism and the risk of breast cancer.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
UGT3 represents one of the most important classes of phase II detoxification enzymes that catalyze the transfer of glucuronic acid to a large number of substrates in the liver and extrahepatic tissues (1) . Compounds inactivated by glucuronic acid conjugation include steroid hormones, such as estrogens and catechol estrogens (2, 3, 4, 5) . Thus UGT enzymes may assist in the maintenance of steady-state levels of steroids in target tissues (6 , 7) . Moreover, there is evidence that one of the UGT1A family members, UGT1A1, is involved in E2 inactivation (8 , 9) and expressed in the mammary gland (8) , and, therefore, represents a good candidate gene in breast carcinogenesis.

Interindividual variation in UGT1A1 expression is explained by a polymorphic alteration in the atypical TATA-box region of the UGT1A1 gene (10, 11, 12) . This polymorphic site is characterized by a variation in the number of TA repeats in the A(TA)nTAA sequence of the promoter. The most common allele (UGT1A1*1) contains six TA repeats, whereas the principal variant allele (UGT1A1*28) contains seven TA repeats. Two other UGT1A1 alleles, the UGT1A1*33 [A(TA)5TAA] allele and the UGT1A1*34 [A(TA)8TAA] allele, have been found almost exclusively in the African-American population (13 , 14) . In a previous study, we investigated the association between breast cancer and A(TA)7TAA and A(TA)8TAA UGT1A1 alleles, which have been shown to have lower transcriptional activity in vitro (8) . In the CBCS study, the alleles A(TA)7TAA and A(TA)8TAA were associated with a 2-fold increase in the risk of developing breast cancer in premenopausal African-American women.

In the present study, we evaluated, among primarily Caucasian women, the relationship between UGT1A1 alleles and breast cancer risk in a nested case-control study within the NHS cohort. Because decreased transcription of the UGT1A1 gene has been found to be associated with increased plasma levels of substrates of the UGT1A1 protein, e.g., bilirubin, we also evaluated the relationship between the UGT1A1*28 allele and circulating estrogen levels and the interaction between UGT1A1 and CYP17 polymorphisms.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Study Population.
The NHS was initiated in 1976, when 121,700 United States registered nurses between the ages of 30 and 55 returned an initial questionnaire reporting medical histories and baseline health-related exposures. Between 1989 and 1990, blood samples were collected from 32,826 women. Incident breast cancers are identified by self-report and confirmed by medical record review. Eligible cases in this study consisted of women from the subcohort with pathologically confirmed incident breast cancer who gave a blood specimen. Controls were matched to cases on the basis of year of birth, menopausal status, and postmenopausal hormone use, as well as time of day, month, and fasting status at blood draw. Menopause was defined as described previously (5) . The nested case-control study consists of 461 incident breast cancer cases and 615 matched controls. The study sample for the plasma hormone analysis was restricted to postmenopausal controls not using hormone replacement therapy within 3 months of blood draw. The protocol was approved by the Committee on Human Subjects, Brigham and Women’s Hospital, Boston, MA. Detailed information on exposure data and hormone assay have been described previously (15) .

Molecular Analysis.
All analyses were conducted with laboratory personnel blinded to case status. DNA was extracted from buffy coat fractions using the QIAGEN QIAamp Blood Kit (QIAGEN, Inc., Chatsworth, CA). DNA samples from cases and controls were genotyped for the dinucleotide insertion/deletion present in the promoter region of the UGT1A1 gene using previously described methods (8) .

Statistical Methods.
ORs and 95% CIs were calculated using conditional and unconditional logistic regression. In addition to the matching variables, we adjusted for the following breast cancer risk factors: (a) BMI (kg/m2) at age 18 (continuous); (b) weight gain since age 18 (<5, 5–19.9, and >=20 kg); (c) age of menarche (<12, 12, 13, and >=13 years); (d) parity/age at first birth (nulliparous; one to two children/age at first birth <=24 years; one to two children/age at first birth >=24 years; three children/age at first birth <=24 years; and three or more children/age at first birth >=24 years); (e) first-degree family history of breast cancer (yes/no); (f) history of benign breast disease (yes/no); and (g) duration of postmenopausal hormone use (never; past, <5 and >=5 years; current, <5 and >=5 years). We also adjusted for age at menopause (continuous in years) in analyses limited to postmenopausal women. Indicator variables for all three genotypes were created using the UGT1A1*1/UGT1A1*1 hypothesized low-risk genotypes as the reference category in the multivariable models. Genotype was also evaluated using a dichotomous variable with the UGT1A1*1/UGT1A1*28 and UGT1A1*28/UGT1A1*28 subjects combined, because a gene dosage effect on breast cancer risk was not apparent. Unconditional multivariable models controlling for the matching factors enabled all controls to be included in analyses, limiting the cases to specified histopathological characteristics. Interactions between genotypes and breast cancer risk factors were evaluated by including interaction terms in multivariate logistic regression models. The likelihood ratio test was used to assess the statistical significance of these interactions.

Mixed regression models were used to evaluate the association between genotype and circulating hormone levels among controls, controlling for BMI at blood draw and the matching variables (16) . Hormone fractions were measured in two to three different batches; the laboratory batch was treated as a random variable in all hormone analyses except for dehydroepiandrosterone sulfate among never-users of hormone replacement, where a batch effect was not observed. We calculated least-square mean plasma steroid hormone levels to evaluate the differences in hormone levels between the genotypes; this was limited to postmenopausal women. The UGT1A1*1/UGT1A1*1 group was used as the reference category. To examine the interactive effect of the UGT1A1 gene and the CYP17 gene on hormone levels, we used the SAS Proc Mixed procedure. The natural logarithm of the plasma hormone values was used in the analyses to reduce the skewness of the regression residuals. We used the SAS statistical package for all analyses (SAS Institute, Inc.).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Five controls and two cases could not be genotyped for UGT1A1 promoter polymorphisms. In addition, because of their very low prevalence, women who had at least one UGT1A1*33 allele [A(TA)5TAA; n = 2; one case and one control] and one UGT1A1*34 allele [A(TA)8TAA; n = 3; two cases and one control] were not included in the analysis. Thus our study included 455 breast cancer cases and 609 controls. A total of 352 cases and 498 controls were postmenopausal, and 63 cases and 68 controls were premenopausal (Table 1)Citation ; menopausal status was uncertain for 40 cases and 43 controls.


View this table:
[in this window]
[in a new window]
  		Table 1 Association between UGT1A1 genotype and breast cancer risk. RRs and 95% CI for breast cancer risk by UGT1A1 genotype and menopausal status

 
The prevalence of the homozygous UGT1A1*28 genotype in the present population was very close to that observed in a population of healthy Europeans [9% in NHS cases and 10% in NHS controls compared with 11.3% in Beutler et al. (13) ]. The calculated frequencies for the UGT1A1*1 and UGT1A1*28 alleles were 0.68 and 0.32, respectively, in the controls and 0.69 and 0.31, respectively, in the cases. Genotype frequencies were in Hardy-Weinberg equilibrium for cases ({chi}2 = 1.49; degrees of freedom (df), 1; P = 0.22) and controls ({chi}2 = 0.80; df, 1; P = 0.37). The prevalence of the UGT1A1*33 and UGT1A1*34 alleles was extremely low in the NHS, which was consistent with the fact that most women self-reported their ethnicity as Caucasian, with very few Asians (0.3%), Hispanics (0.1%), and African Americans (0.3%). The prevalence of the lower-transcriptional activity alleles was slightly higher in the African-American population (0.40 in the CBCS control group; Ref. 8 ) compared with the Caucasian population (0.32 for the NHS control group).

There was no significant association between the low-activity allele, UGT1A1*28 [A(TA)7TAA], and breast cancer (Table 1)Citation . Compared with women homozygous for the UGT1A1*1 allele, the estimated RR for the UGT1A1*28/*28 genotype was 0.80 (CI, 0.49–1.29). A slightly but nonsignificantly higher RR was observed among premenopausal homozygotes (UGT1A1*28/*28 versus *1/*1; RR = 1.28; CI, 0.38–4.64) compared with postmenopausal women (RR = 0.80; CI, 0.47–1.36). No association was revealed in subgroups defined by age at menarche, menopausal status, and clinical and pathological characteristics. We observed that having both polymorphisms in UGT1A1 (UGT1A1*28) and CYP17 (A2 polymorphism) did not affect the risk of developing breast cancer.

In the analysis of the relationship of genotype with plasma steroid hormone levels, we calculated least-square geometric mean levels for each UGT1A1 genotype among postmenopausal women not currently using postmenopausal hormones (Table 2)Citation . Compared with women with the UGT1A1*1/UGT1A1*1 genotype, women with the UGT1A1*1/UGT1A1*28 and UGT1A1*28/UGT1A1*28 genotypes had nonsignificant elevated levels of E1: 4.4% (P = 0.38) and 8.0% (P = 0.15), respectively. Because the synthesis of estrogens occurs principally in the adipose tissue in postmenopausal women, stratification was done according to BMI at blood draw (BMIs <=23 kg/m2, >23 kg/m2 and <=27 kg/m2, and >27 kg/m2). Comparing women with low (BMI <=23 kg/m2) versus high (BMI >27 kg/m2) estrogen production, the elevation of circulating E2 levels was greater in women who had at least one UGT1A1*28 allele (87.9%) compared with UGT1A1*1 homozygous women (52.4%). Within BMI subgroups, women who had at least one UGT1A1*28 allele in the highest stratum of BMI (>27 kg/m2) had a nonsignificant increase in the level of E2 (17.5%; P = 0.09) compared with UGT1A1*1 homozygous women (Table 2)Citation . Furthermore, we evaluated the combination of UGT1A1 and CYP17 genotypes on hormone levels. In analyses limited to women with a BMI >27 kg/m2 who had at least one UGT1A1*28 and one CYP17 A2 allele (n = 30), there was a marginally significant increase in the levels of E1 (33.2%; P = 0.07) and a nonsignificant elevation in E2 (27.9%; P = 0.18) compared with UGT1A1*1 and CYP17 A1 homozygous carriers (n = 20).


View this table:
[in this window]
[in a new window]
  		Table 2 Least-square geometric mean hormone levels among postmenopausal women not currently using postmenopausal hormones by UGT1A1 and CYP17 genotypes

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
An important role for the UGT enzymes is to maintain intracellular steady-state levels of steroids, including estrogens, in target tissues (6 , 7) . Accordingly, high levels of estrogen-glucuronides have been observed in breast cyst fluid, suggesting their formation within the mammary gland (17 , 18) . We hypothesized that alteration in the glucuronidation pathway, which directly inactivates estrogens and catechol metabolites at their site of action (2, 3, 4, 5) , may potentially modify estrogen concentration and consequently estrogen-related cancer risk. Functional analyses of the transcriptional promoter activity demonstrated that allele UGT1A1*28 has a 30% decrease in transcription and that the UGT1A1*34 allele has a 50% decreased transcription, whereas the allele UGT1A1*33 has a 20% increased transcription compared with the UGT1A1*1 wild-type allele (8) . Additional studies based on phenotypic measurements revealed that those who were carriers of at least one UGT1A1*28 allele had much lower glucuronidation rates compared with homozygous UGT1A1*1 (19 , 20) . On the basis of these functional studies (8 , 13) , women who had at least one low-transcriptional allele UGT1A1*28 [A(TA)7TAA] were compared with women who had high-activity alleles UGT1A1*1 [A(TA)6TAA]. The present study extends previous work among African-American women (200 cases and 200 controls) in the CBCS. In the CBCS study, the low-activity UGT1A1 alleles were positively associated with invasive breast cancer among premenopausal women (OR, 1.8; 95% CI, 1.0–3.1; P = 0.06; Ref. 8 ), particularly among women with estrogen receptor-negative breast cancer (OR, 2.1; 95% CI, 1.0–4.2; P = 0.04) compared with estrogen receptor-positive breast cancer (OR, 1.3; 95% CI, 0.6–3.0; P = 0.5). In contrast, in the present NHS, a larger population-based prospective study, no influence of the UGT1A1 polymorphism was observed on the susceptibility to breast cancer. Furthermore, we found no interaction between the UGT1A1*28 and the CYP17 A2 allele in relation to breast cancer risk.

In the analysis of hormone levels and UGT genotype among postmenopausal women not taking hormone replacement therapy, we observed a moderate increase in the levels of E1 and E2 associated with the UGT1A1*28 allele alone and in combination with CYP17 A2 polymorphism only in overweight women (BMI >27 kg/m2). However, this modest elevation in the plasma levels of estrogenic hormones in postmenopausal women may be insufficient for us to detect an altered risk of breast cancer. It is also well known that different UGT enzymes possess overlapping substrate specificity, including reactivity for estrogenic hormones (5) . In the case of E2 glucuronidation, although UGT1A1 is the major UGT reported to date to actively conjugate E2 (8 , 9) , other existing or not yet isolated UGTs may have a higher specificity and/or efficacy toward this steroid molecule (2 , 21) . In that case, a partial deficiency in UGT1A1, such as the one studied here, would have a limited impact on E2 metabolism and, consequently, on breast cancer risk. The modest additional elevation of E2 among the heaviest women who are carriers of at least one UGT1A1*28 allele is suggestive of a possible contribution of the glucuronidation pathway, and especially of UGT1A1, in the maintenance of hormone homeostasis in situations where estrogens are present at higher concentrations.

Our results suggest that the decrease in transcription of the UGT1A1 gene caused by the TA polymorphism is not sufficient to alter breast cancer risk in Caucasian women.


   Acknowledgments
 
We thank the participants of the Nurses’ Health Study for their continuing exceptional cooperation; Lisa Li for technical assistance; and Frank Speizer, principal investigator of the Nurses’ Health Study, for his support.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by the Medical Research Council of Canada (to C. G.) and NIH Grants CA40356, CA49449, and CA65725. Back

2 To whom requests for reprints should be addressed, at Oncology and Molecular Endocrinology Research Center, Laval University Medical Center (CHUL), Faculty of Pharmacy, Laval University, Quebec G1V 4G2, Canada. E-mail: chantal.guillemette{at}crchul.ulaval.ca Back

3 The abbreviations used are: UGT, UDP-glucuronosyltransferase enzyme; NHS1, Nurses’ Health Study 1; OR, odds ratio; CI, confidence interval; CYP17, cytochrome p450c17{alpha}; CBCS, North Carolina Breast Cancer Study; E2, estradiol; E1, estrone; BMI, body mass index; RR, relative risk. Back

Received 11/17/00; revised 3/23/01; accepted 4/ 9/01.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Dutton G. J. eds. . Glucuronidation of Drugs and Other Compounds, : CRC Press, Inc. Boca Raton, FL 1980.
  2. Albert C., Vallee M., Beaudry G., Belanger A., Hum D. W. The monkey and human uridine diphosphate-glucuronosyltransferase UGT1A9, expressed in steroid target tissues, are estrogen-conjugating enzymes. Endocrinology, 140: 3292-3302, 1999.[Abstract/Free Full Text]
  3. Ritter J. K., Chen F., Sheen Y. Y., Lubet R. A., Owens I. S. Two human liver cDNAs encode UDP-glucuronosyltransferases with 2 log differences in activity toward parallel substrates including hyodeoxycholic acid and certain estrogen derivatives. Biochemistry, 31: 3409-3414, 1992.[Medline]
  4. Ritter J. K., Sheen Y. Y., Owens I. S. Cloning and expression of human liver UDP-glucuronosyltransferase in COS-1 cells: 3,4-catechol estrogens and estriol as primary substrates. J. Biol. Chem., 265: 7900-7906, 1990.[Abstract/Free Full Text]
  5. Cheng Z., Rios G., King C., Coffman B., Green M., Mojarrabi B., Mackenzie P., Tephly T. Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7. J. Toxicol. Sci., 45: 52-57, 1998.
  6. Hum D. W., Bélanger A., Lévesque E., Barbier O., Beaulieu M., Albert A., Vallée M., Guillemette C., Tchernof A., Turgeon D., Dubois S. Characterization of UDP-glucuronosyltransferases active on steroid hormones. J. Steroid Biochem. Mol. Biol., 69: 413-423, 1999.[Medline]
  7. Bélanger A., Hum D. W., Beaulieu M., Lévesque É., Guillemette C., Tchernof A., Bélanger G., Turgeon D., Dubois S. Characterization and regulation of UDP-glucuronosyltransferases in steroid target tissues. J. Steroid Biochem. Mol. Biol., 65: 301-310, 1998.[Medline]
  8. Guillemette C., Millikan R., Newman B., Housman D. Genetic polymorphisms in UGT1A1 and association with breast cancer among African Americans. Cancer Res., 60: 950-956, 2000.[Abstract/Free Full Text]
  9. Senafi S. B., Clarke D. J., Burchell B. Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem. J., 303: 233-240, 1994.
  10. Bosma P., Chowdhury J., Jansen P. Genetic inheritance of Gilbert’s syndrome. Lancet, 346: 314-315, 1995.[Medline]
  11. Bosma P. J., Chowdhury R. J., Bakker C. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N. Engl. J. Med., 333: 1171-1175, 1995.[Abstract/Free Full Text]
  12. Monaghan G., Ryan M., Seddon R., Hume R., Burchell B. Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert’s syndrome. Lancet, 347: 578-581, 1996.[Medline]
  13. Beutler E., Gelbart T., Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?. Proc. Natl. Acad. Sci. USA, 95: 8170-8174, 1998.[Abstract/Free Full Text]
  14. Lampe J. W., Bigler J., Horner N. K., Potter J. D. UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics, 9: 341-349, 1999.[Medline]
  15. Haiman C., Hankinson S., Spiegelman D., Colditz G., Willett W., Speizer F., Kelsey K., Hunter D. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res., 59: 1015-1020, 1999.[Abstract/Free Full Text]
  16. SAS Institute, Inc. Changes and Enhancements. SAS Technical Report, Release 6.07. 1992.
  17. Bélanger A., Caron S., Labrie F., Naldoni C., Dogliotti L., Angeli A. Levels of eighteen nonconjugated and conjugated steroids in human breast cyst fluid: relationships with cyst type. Eur. J. Cancer, 26: 277-281, 1990.
  18. Bélanger A., Labrie F., Angeli A. Unconjugated and glucuronide steroid levels in human breast cyst fluid. Ann. NY Acad. Sci., 586: 93-100, 1990.[Abstract]
  19. Iyer L., Hall D., Das S., Mortell M. A., Ramirez J., Kim S., Di Rienzo A., Ratain M. J. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin. Pharmacol. Ther., 65: 576-582, 1999.[Medline]
  20. Biondi M., Turri O., Dilillo D., Stival G., Guagnellini E. Contribution of the TATA-box genotype (Gilbert syndrome) to serum bilirubin concentrations in the Italian population. Clin. Chem., 45: 897-898, 1999.[Free Full Text]
  21. Gall W. E., Zawada G., Mojarrabi B., Tephly T. R., Green M. D., Coffman B. L., Mackenzie P. I., Radominska-Pandya A. Differential glucuronidation of bile acids, androgens, and estrogens by human UGT1A3 and 2B7. J. Steroid Biochem. Mol. Biol., 70: 101-108, 1999.[Medline]



This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. L. Deming, W. Zheng, W.-H. Xu, Q. Cai, Z. Ruan, Y.-B. Xiang, and X.-O. Shu
UGT1A1 Genetic Polymorphisms, Endogenous Estrogen Exposure, Soy Food Intake, and Endometrial Cancer Risk
Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 563 - 570.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. L. Hong, D. Huo, H.-J. Kim, Q. Niu, D. L. Fackenthal, S. A. Cummings, E. M. John, D. W. West, A. S. Whittemore, S. Das, et al.
UDP-Glucuronosyltransferase 1A1 Gene Polymorphisms and Total Bilirubin Levels in an Ethnically Diverse Cohort of Women
Drug Metab. Dispos., August 1, 2007; 35(8): 1254 - 1261.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
J.-L. Chang, J. Bigler, Y. Schwarz, S. S. Li, L. Li, I. B. King, J. D. Potter, and J. W. Lampe
UGT1A1 Polymorphism Is Associated with Serum Bilirubin Concentrations in a Randomized, Controlled, Fruit and Vegetable Feeding Trial
J. Nutr., April 1, 2007; 137(4): 890 - 897.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. J. Ratain
From bedside to bench to bedside to clinical practice: an odyssey with irinotecan.
Clin. Cancer Res., March 15, 2006; 12(6): 1658 - 1660.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Thibaudeau, J. Lepine, J. Tojcic, Y. Duguay, G. Pelletier, M. Plante, J. Brisson, B. Tetu, S. Jacob, L. Perusse, et al.
Characterization of Common UGT1A8, UGT1A9, and UGT2B7 Variants with Different Capacities to Inactivate Mutagenic 4-Hydroxylated Metabolites of Estradiol and Estrone
Cancer Res., January 1, 2006; 66(1): 125 - 133.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
D. French, M. R. Wilkinson, W. Yang, L. de Chaisemartin, E. H. Cook, S. Das, M. J. Ratain, W. E. Evans, J. R. Downing, C.-H. Pui, et al.
Global gene expression as a function of germline genetic variation
Hum. Mol. Genet., June 15, 2005; 14(12): 1621 - 1629.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
S. Peterson, J. Bigler, N. K. Horner, J. D. Potter, and J. W. Lampe
Cruciferae Interact with the UGT1A1*28 Polymorphism to Determine Serum Bilirubin Levels in Humans
J. Nutr., May 1, 2005; 135(5): 1051 - 1055.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
L. Vitek
Impact of Serum Bilirubin on Human Diseases
Pediatrics, May 1, 2005; 115(5): 1411 - 1412.
[Full Text] [PDF]

Home page
 CarcinogenesisHome page
E.M.J. van der Logt, S.M. Bergevoet, H.M.J. Roelofs, Z. van Hooijdonk, R.H.M. te Morsche, T. Wobbes, J.B. de Kok, F.M. Nagengast, and W.H.M. Peters
Genetic polymorphisms in UDP-glucuronosyltransferases and glutathione S-transferases and colorectal cancer risk
Carcinogenesis, December 1, 2004; 25(12): 2407 - 2415.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Lepine, O. Bernard, M. Plante, B. Tetu, G. Pelletier, F. Labrie, A. Belanger, and C. Guillemette
Specificity and Regioselectivity of the Conjugation of Estradiol, Estrone, and Their Catecholestrogen and Methoxyestrogen Metabolites by Human Uridine Diphospho-glucuronosyltransferases Expressed in Endometrium
J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5222 - 5232.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
P. G. Wells, P. I. Mackenzie, J. Roy Chowdhury, C. Guillemette, P. A. Gregory, Y. Ishii, A. J. Hansen, F. K. Kessler, P. M. Kim, N. Roy Chowdhury, et al.
GLUCURONIDATION AND THE UDP-GLUCURONOSYLTRANSFERASES IN HEALTH AND DISEASE
Drug Metab. Dispos., March 1, 2004; 32(3): 281 - 290.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Duguay, M. McGrath, J. Lepine, J.-F. Gagne, S. E. Hankinson, G. A. Colditz, D. J. Hunter, M. Plante, B. Tetu, A. Belanger, et al.
The Functional UGT1A1 Promoter Polymorphism Decreases Endometrial Cancer Risk
Cancer Res., February 1, 2004; 64(3): 1202 - 1207.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J.-L. Fang and P. Lazarus
Correlation between the UDP-Glucuronosyltransferase (UGT1A1) TATAA Box Polymorphism and Carcinogen Detoxification Phenotype: Significantly Decreased Glucuronidating Activity against Benzo(a)pyrene-7,8-dihydrodiol(-) in Liver Microsomes from Subjects with the UGT1A1*28 Variant
Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 102 - 109.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
M M de Jong, I M Nolte, G J te Meerman, W T A van der Graaf, J C Oosterwijk, J H Kleibeuker, M Schaapveld, and E G E de Vries
Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility
J. Med. Genet., April 1, 2002; 39(4): 225 - 242.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guillemette, C.
Right arrow Articles by Hunter, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guillemette, C.
Right arrow Articles by Hunter, D. J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online